Skip to main content
Log in

Calciphylaxis: evolving concepts

  • Clinical Letters
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Essary LR, Wick MR. Cutaneous calciphylaxis. An underrecognized clinicopathologic entity.Am J Clin Pathol 2000; 113: 280–7.

    Article  PubMed  CAS  Google Scholar 

  2. Budisaljevic MN, Cheek C, Ploth DW. Calciphylaxis in chronic renal failure.J Am Soc Nephrol 1996; 7: 978–82.

    Google Scholar 

  3. Llach F. Calcific uremic arteriolopathy (calciphylaxis): an evolving entity?Am J Kidney Dis 1998; 32: 514–8.

    Article  PubMed  CAS  Google Scholar 

  4. Mazhar AR, Johnson RJ, Gillen D, et al. Risk factors and mortality associated with calciphylaxis in end-stage renal disease.Kidney Int 2001; 60: 324–32.

    Article  PubMed  CAS  Google Scholar 

  5. Davies MR, Hruska KA. Pathophysiological mechanisms of vascular calcification in end-stage renal disease.Kidney Int 2001; 60: 472–9.

    Article  PubMed  CAS  Google Scholar 

  6. Giachelli CM, Speer MY, Li X, Rajachar RM, Yang H. Regulation of vascular calcification. Roles of phosphate and osteopontin.Circ Res 2005; 96: 717–22.

    Article  PubMed  CAS  Google Scholar 

  7. Ahmed S, O’Neill KD, Hood AF, Evan AP, Moe SM. Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells.Am J Kidney Dis 2001; 37: 1267–76.

    Article  PubMed  CAS  Google Scholar 

  8. Schäfer C, Heiss A, Schwarz A, et al. The serum protein α2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification.J Clin Invest 2003; 112: 357–66.

    PubMed  Google Scholar 

  9. Ketteler M, Bongartz P, Westenfeld R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a crosssectional study.Lancet 2003;361:827–33.

    Article  PubMed  CAS  Google Scholar 

  10. Stenvinkel P, Wang K, Qureshi AR, et al. Low fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin.Kidney Int 2005; 67: 2383–92.

    Article  PubMed  CAS  Google Scholar 

  11. Fine A, Zacharias J. Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int 2002; 61: 2210–17.

    Article  PubMed  Google Scholar 

  12. Wilmer WA, Magro CM. Calciphylaxis: emerging concepts in prevention, diagnosis, and treatment.Semin Dial 2002; 15: 172–86.

    Article  PubMed  Google Scholar 

  13. Llach F. The evolving pattern of calciphylaxis: therapeutic considerations.Nephrol Dial Transplant 2001; 16: 448–51.

    Article  PubMed  CAS  Google Scholar 

  14. Monney P, Nguyen QV, Perroud H, Descombes E. Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure.Nephrol Dial Transplant 2004; 19: 2130–2.

    Article  PubMed  Google Scholar 

  15. Green JA, Green CR, Minott SD. Calciphylaxis treated with neurolytic lumbar sympathetic block: case report and review of the literature.Reg Anesth Pain Med 2000; 25: 310–2.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Giovanni Garini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Garini, G., Galletti, E., Ricci, R. et al. Calciphylaxis: evolving concepts. Int Emergency Med 1, 320–322 (2006). https://doi.org/10.1007/BF02934772

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02934772

Keywords

Navigation